190 related articles for article (PubMed ID: 22609829)
21. The Epstein-Barr virus latent membrane protein 2A PY motif recruits WW domain-containing ubiquitin-protein ligases.
Ikeda M; Ikeda A; Longan LC; Longnecker R
Virology; 2000 Mar; 268(1):178-91. PubMed ID: 10683340
[TBL] [Abstract][Full Text] [Related]
22. Epstein-Barr virus LMP2A reduces hyperactivation induced by LMP1 to restore normal B cell phenotype in transgenic mice.
Vrazo AC; Chauchard M; Raab-Traub N; Longnecker R
PLoS Pathog; 2012; 8(4):e1002662. PubMed ID: 22536156
[TBL] [Abstract][Full Text] [Related]
23. The effects of the Epstein-Barr virus latent membrane protein 2A on B cell function.
Merchant M; Swart R; Katzman RB; Ikeda M; Ikeda A; Longnecker R; Dykstra ML; Pierce SK
Int Rev Immunol; 2001; 20(6):805-35. PubMed ID: 11913951
[TBL] [Abstract][Full Text] [Related]
24. Epstein-Barr virus latent membrane protein 2A activates beta-catenin signaling in epithelial cells.
Morrison JA; Klingelhutz AJ; Raab-Traub N
J Virol; 2003 Nov; 77(22):12276-84. PubMed ID: 14581564
[TBL] [Abstract][Full Text] [Related]
25. Epstein-Barr virus LMP2A drives B cell development and survival in the absence of normal B cell receptor signals.
Caldwell RG; Wilson JB; Anderson SJ; Longnecker R
Immunity; 1998 Sep; 9(3):405-11. PubMed ID: 9768760
[TBL] [Abstract][Full Text] [Related]
26. A shared gene expression signature in mouse models of EBV-associated and non-EBV-associated Burkitt lymphoma.
Bieging KT; Fish K; Bondada S; Longnecker R
Blood; 2011 Dec; 118(26):6849-59. PubMed ID: 22039254
[TBL] [Abstract][Full Text] [Related]
27. Selective efficacy of depsipeptide in a xenograft model of Epstein-Barr virus-positive lymphoproliferative disorder.
Roychowdhury S; Baiocchi RA; Vourganti S; Bhatt D; Blaser BW; Freud AG; Chou J; Chen CS; Xiao JJ; Parthun M; Chan KK; Eisenbeis CF; Ferketich AK; Grever MR; Chen CS; Caligiuri MA
J Natl Cancer Inst; 2004 Oct; 96(19):1447-57. PubMed ID: 15467034
[TBL] [Abstract][Full Text] [Related]
28. Epstein-Barr virus LMP2A-induced B-cell survival in two unique classes of EmuLMP2A transgenic mice.
Caldwell RG; Brown RC; Longnecker R
J Virol; 2000 Feb; 74(3):1101-13. PubMed ID: 10627520
[TBL] [Abstract][Full Text] [Related]
29. Epstein-Barr virus in Burkitt's lymphoma: a role for latent membrane protein 2A.
Bieging KT; Swanson-Mungerson M; Amick AC; Longnecker R
Cell Cycle; 2010 Mar; 9(5):901-8. PubMed ID: 20160479
[TBL] [Abstract][Full Text] [Related]
30. Epstein-Barr virus LMP2A increases IL-10 production in mitogen-stimulated primary B-cells and B-cell lymphomas.
Incrocci R; McCormack M; Swanson-Mungerson M
J Gen Virol; 2013 May; 94(Pt 5):1127-1133. PubMed ID: 23303827
[TBL] [Abstract][Full Text] [Related]
31. The LMP2A signalosome--a therapeutic target for Epstein-Barr virus latency and associated disease.
Portis T; Cooper L; Dennis P; Longnecker R
Front Biosci; 2002 Feb; 7():d414-26. PubMed ID: 11815296
[TBL] [Abstract][Full Text] [Related]
32. Mouse model of Epstein-Barr virus LMP1- and LMP2A-driven germinal center B-cell lymphoproliferative disease.
Minamitani T; Ma Y; Zhou H; Kida H; Tsai CY; Obana M; Okuzaki D; Fujio Y; Kumanogoh A; Zhao B; Kikutani H; Kieff E; Gewurz BE; Yasui T
Proc Natl Acad Sci U S A; 2017 May; 114(18):4751-4756. PubMed ID: 28351978
[TBL] [Abstract][Full Text] [Related]
33. PY motifs of Epstein-Barr virus LMP2A regulate protein stability and phosphorylation of LMP2A-associated proteins.
Ikeda M; Ikeda A; Longnecker R
J Virol; 2001 Jun; 75(12):5711-8. PubMed ID: 11356981
[TBL] [Abstract][Full Text] [Related]
34. Epstein-Barr virus LMP2A alters in vivo and in vitro models of B-cell anergy, but not deletion, in response to autoantigen.
Swanson-Mungerson MA; Caldwell RG; Bultema R; Longnecker R
J Virol; 2005 Jun; 79(12):7355-62. PubMed ID: 15919890
[TBL] [Abstract][Full Text] [Related]
35. Transcriptome changes induced by Epstein-Barr virus LMP1 and LMP2A in transgenic lymphocytes and lymphoma.
Shair KH; Raab-Traub N
mBio; 2012; 3(5):. PubMed ID: 22991431
[TBL] [Abstract][Full Text] [Related]
36. Epstein-Barr virus (EBV) LMP2A mediates B-lymphocyte survival through constitutive activation of the Ras/PI3K/Akt pathway.
Portis T; Longnecker R
Oncogene; 2004 Nov; 23(53):8619-28. PubMed ID: 15361852
[TBL] [Abstract][Full Text] [Related]
37. EBNA2-deleted Epstein-Barr virus (EBV) isolate, P3HR1, causes Hodgkin-like lymphomas and diffuse large B cell lymphomas with type II and Wp-restricted latency types in humanized mice.
Li C; Romero-Masters JC; Huebner S; Ohashi M; Hayes M; Bristol JA; Nelson SE; Eichelberg MR; Van Sciver N; Ranheim EA; Scott RS; Johannsen EC; Kenney SC
PLoS Pathog; 2020 Jun; 16(6):e1008590. PubMed ID: 32542010
[TBL] [Abstract][Full Text] [Related]
38. Downregulation of HLA-ABC expression through promoter hypermethylation and downmodulation of MIC-A/B surface expression in LMP2A-positive epithelial carcinoma cell lines.
Singh S; Banerjee S
Sci Rep; 2020 Mar; 10(1):5415. PubMed ID: 32214110
[TBL] [Abstract][Full Text] [Related]
39. Regulation of DNA Damage Signaling and Cell Death Responses by Epstein-Barr Virus Latent Membrane Protein 1 (LMP1) and LMP2A in Nasopharyngeal Carcinoma Cells.
Wasil LR; Wei L; Chang C; Lan L; Shair KH
J Virol; 2015 Aug; 89(15):7612-24. PubMed ID: 25972552
[TBL] [Abstract][Full Text] [Related]
40. Epstein-Barr Virus Latent Membrane Protein 2A (LMP2A) Enhances ATP Production in B Cell Tumors through mTOR and HIF-1α.
Incrocci R; Monroy Del Toro R; Devitt G; Salimian M; Braich K; Swanson-Mungerson M
Int J Mol Sci; 2024 Apr; 25(7):. PubMed ID: 38612754
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
